The FDA has approved a fifth vaccine for immunization against the 2009 H1N1 (swine) influenza virus from ID Biomedical Corporation, owned by GlaxoSmithKline. As with the four previous H1N1 influenza vaccines licensed by the FDA on September 15, 2009, ID Biomedical will manufacture its H1N1 vaccine using the established, licensed egg-based manufacturing process used for producing seasonal flu vaccine. ID Biomedical’s H1N1 monovalent vaccine will be produced in multi-dose vials, in a formulation that contains thimerosal.

For more information visit